novo nordisk semaglutide ozempic - Search News

The New York Times · 1d

Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Fortune on MSN · 1d

As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market. The drug is more potent than Ozempic and Wegovy, expanding treatment to heavier patients while perhaps reducing treatment times for other individuals.

Reuters on MSN · 2d

Novo Nordisk sees slower sales growth in 2025

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Wegovy maker Novo Nordisk on Wednesday forecast sales would grow at a slower rate this year although the outlook was roughly in line with market expectations as the pace of ferocious demand for its wildly popular obesity drug Wegovy eases somewhat.

1don MSN

Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

9don MSN

Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Pharmaceutical Technology on MSN8d

Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD

The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D ...

Novo Nordisk expands Ozempic's turf with new FDA nod to curb kidney disease risks

When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...

9don MSN

FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

5h

Denmark Could Ban Or Push Ozempic, Wegovy And Shipping Prices Through The Roof If Trump Escalates Over Greenland

Donald Trump 's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...

1don MSN

Why Novo Nordisk Stock Is Soaring Today

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

14h

Ozempic Could Get Way Too Expensive Under Trump—Here's What You Can Do

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

1d

Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

1don MSN

Novo Nordisk Outlook Provides Some Welcome Relief

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results